Pharmacologic Treatment of Urea Cycle Disorders
Customize your policy alerts
Sign up for premerabluecrossofwashington Policy 5.01.611 alerts
Get alerted when Policy 5.01.611 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-necessity coverage and authorization requirements for drugs used to treat urea cycle disorders, hyperammonemia, hyperargininemia, and specified organic acidemias. It applies to providers requesting coverage under the pharmacy or medical benefit.
The Ravicti criterion was updated from requiring failure of Buphenyl to requiring failure of generic sodium phenylbutyrate.
Carbaglu was given an added indication for acute hyperammonemia due to propionic acidemia or methylmalonic acidemia when used with standard-of-care treatment.
Pheburane was added for treatment of urea cycle disorders in adult and pediatric individuals.
Added coverage for Loargys (pegzilarginase-nbln) for the treatment of hyperargininemia.
Added generic glycerol phenylbutyrate with the same criteria as Ravicti (glycerol phenylbutyrate).
Clarified that non-formulary exception review authorizations for drugs listed in the policy may be approved for up to 12 months.
Clarified that medications listed in the policy are subject to the product's FDA dosage and administration prescribing information.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.